Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tretazicar + caricotamide
- Development stage
- Preclinical
- Lead developer
- BTG International
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Topical
01
Overview
Tretazicar + caricotamide is an investigational combination therapy composed of the prodrug tretazicar (also known as CB1954) and the cosubstrate caricotamide (EP-0152R). Tretazicar is a dinitrobenzamide derivative that acts as a prodrug; it requires enzymatic activation by quinone oxidoreductase 2 (NQO2), which uses caricotamide as an electron donor. Upon activation, tretazicar forms a bifunctional alkylating agent that induces DNA cross-linking and subsequent apoptosis in target cells. This mechanism has been explored primarily for antineoplastic activity in liver cancer and for anti-parasitic effects in cutaneous leishmaniasis models. The combination demonstrates synergistic efficacy compared to monotherapy with either agent alone[1][5][6][9].
- Brand names
- Prolarix
- Other names
- tretazicar + caricotamideCB 1954 + EP-0152R
02
Targets
NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])DNA
Beyond the preview
Go deeper on tretazicar + caricotamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tretazicar + caricotamide.